Pathological complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
© Byrski et al. 2015
Published: 26 November 2015
To estimate the frequency of pathologic complete response (pCR) after neoadjuvant treatment with cisplatin chemotherapy in women with breast cancer and who are BRCA1 mutation carriers.
Patients and Methods
107 women with BRCA1 mutation and affected with breast cancer, who presented with stage I to III breast cancer between December 2006 and June 2014 received treatment with cisplatin 75 mg/m2 every three weeks for four cycles, followed by mastectomy and conventional chemotherapy (AC). Information on clinical stage, grade, hormone receptor status and HER2 status was collected prior to treatment. Review of surgical samples was done in order to determine the pathologic complete response.
107 patients were included in the study. 93 patients were treated for first primary breast cancer and 14 patients had previously received treatment for a prior cancer. A pathologic complete response was observed in 65 of the 107 patients (61%).
In a high proportion of patients with BRCA1-associated breast cancer platinum-based chemotherapy is an effective method of treatment.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.